Comparison of Postoperative Pain and Adverse Effects between Variable-Rate Feedback Infusion and Conventional Fixed-Rate Basal Infusion Modes of Patient-Controlled Epidural Analgesia following Open Gastrectomy: A Randomized Controlled Trial by 김나영 et al.




Comparison of Postoperative Pain and Adverse Effects between
Variable-Rate Feedback Infusion and Conventional Fixed-Rate
Basal Infusion Modes of Patient-Controlled Epidural Analgesia
Following Open Gastrectomy: A Randomized Controlled Trial
Yoo Kyung Jang 1,† , Na Young Kim 2,† , Jeong Soo Lee 2 , Hye Jung Shin 3 , Hyoung Gyun Kim 1,
Suk Woo Lee 1, Jae Chul Koh 1,* and Young Chul Yoo 2,*


Citation: Jang, Y.K.; Kim, N.Y.; Lee,
J.S.; Shin, H.J.; Kim, H.G.; Lee, S.W.;
Koh, J.C.; Yoo, Y.C. Comparison of
Postoperative Pain and Adverse
Effects between Variable-Rate
Feedback Infusion and Conventional




Controlled Trial. Int. J. Environ. Res.






Kazimierz Widenka and Michał Borys
Received: 5 July 2021
Accepted: 15 August 2021
Published: 19 August 2021
Publisher’s Note: MDPI stays neutral
with regard to jurisdictional claims in
published maps and institutional affil-
iations.
Copyright: © 2021 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).
1 Department of Anesthesiology and Pain Medicine, Korea University College of Medicine, 73 Goryeodae-ro,
Seongbuk-gu, Seoul 02841, Korea; gamtang@korea.ac.kr (Y.K.J.); yjgim0912@naver.com (H.G.K.);
sunday249@gmail.com (S.W.L.)
2 Department of Anesthesiology and Pain Medicine, Anesthesia and Pain Research Institute, Yonsei University
College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea; knnyyy@yuhs.ac (N.Y.K.);
ration99@yuhs.ac (J.S.L.)
3 Biostatistics Collaboration Unit, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu,
Seoul 03722, Korea; hjshin105@yuhs.ac
* Correspondence: jaykoh@korea.ac.kr (J.C.K.); seaoyster@yuhs.ac (Y.C.Y.); Tel.: +82-920-5632 (J.C.K.);
+82-2228-4435 (Y.C.Y.)
† These authors contributed equally to this work.
Abstract: Patient-controlled epidural analgesia is widely used to control postoperative pain following
major intra-abdominal surgeries. However, determining the optimal infusion dose that can produce
effective analgesia while reducing side effects remains a task to be solved. Postoperative pain and
adverse effects between variable-rate feedback infusion (VFIM group, n = 36) and conventional
fixed-rate basal infusion (CFIM group, n = 36) of fentanyl/ropivacaine-based patient-controlled
epidural analgesia were evaluated. In the CFIM group, the basal infusion rate was fixed (5 mL/h),
whereas, in the VFIM group, the basal infusion rate was increased by 0.5 mL/h each time a bolus
dose was administered and decreased by 0.3 mL/h when a bolus dose was not administered for 2 h.
Patients in the VFIM group experienced significantly less pain at one to six hours after surgery than
those in the CFIM group. Further, the number of patients who suffered from postoperative nausea
was significantly lower in the VFIM group than in the CFIM group until six hours after surgery. The
variable-rate feedback infusion mode of patient-controlled epidural analgesia may provide better
analgesia accompanied with significantly less nausea in the early postoperative period than the
conventional fixed-rate basal infusion mode following open gastrectomy.
Keywords: postoperative pain; postoperative nausea; background infusion; patient-controlled
epidural analgesia; open gastrectomy
1. Introduction
Patient-controlled epidural analgesia (PCEA) has been widely used to control postop-
erative pain following major intra-abdominal surgeries [1,2]. It is well known that patients
who undergo open gastrectomy often experience substantial postoperative pain; thus,
management of adequate pain is essential to facilitate early postoperative recovery [3]. It
is also known that administration of epidural local anesthetics with opioids to patients
undergoing abdominal surgery reduces postoperative pain when compared with that of
systemic or epidural opioids or epidural local anesthetics alone [4].
For PCEA, a demand dose with or without continuous basal infusion is commonly
used [5]. However, a demand dose mode without basal infusion is difficult to control
the breakthrough pain that occurs when the patient coughs or moves [6]. In addition, it
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may not be effective while sleeping because it relies on the patient’s intention to press the
button [7]. Moreover, the number of analgesics consumed may increase [8]. Therefore,
PCEA using a demand dose with a continuous basal infusion at a constant rate has been
widely used. However, determining the appropriate basal infusion rate for PCEA remains
controversial. If a basal infusion is set lower than the requirement, analgesia may be
insufficient. In contrast, side effects such as postoperative nausea and vomiting (PONV),
sedation, dizziness, hypotension, and respiratory depression may occur when the infusion
rate is too high [9,10].
Determining an optimal infusion dose that can produce effective analgesia while
reducing side effects remains a task to be solved. Since the patient-related factors that
determine the pharmacokinetic/dynamics of PCEA drugs, such as body mass index (BMI),
sex, fat proportion, and age, are very diverse, it is challenging to determine the optimal
infusion dose [11–13].
Recently, a new PCA device that comprises an “optimizing background infusion
mode” was introduced, which can adjust the background infusion rate depending on bolus
demand over a predefined time [14,15]. However, this mode is yet to be applied in PCEA
for postoperative pain control, and there is a dearth of literature on its efficacy and adverse
effects [8,14,15].
The aim of the present study is to compare the postoperative analgesic efficacy and
incidence of nausea between the variable-rate feedback infusion mode (VFIM) and conven-
tional fixed-rate infusion mode (CFIM) of ropivacaine/fentanyl-based PCEA in patients
who underwent open gastrectomy.
2. Materials and Methods
2.1. Study Population
This prospective, randomized controlled trial was approved by the Institutional Re-
view Board (IRB) and Hospital Research Ethics Committee of Severance Hospital, Yonsei
University Health System, Seoul, Korea (IRB protocol No. 4-2016-1152). The trial was regis-
tered at the ClinicalTrials.gov Protocol Registration System (registration no. NCT03430440).
Written informed consent was obtained from all participants, and the study was conducted
in accordance with the principles of the Helsinki Declaration.
A total of 76 American Society of Anesthesiologists (ASA) physical status I-III patients
(aged 20–70 years), who were scheduled for elective open gastrectomy, were enrolled
between December 2017 and January 2019. The exclusion criteria were history of hemato-
logic clotting defects, sepsis, distant metastasis, allergy to PCEA drugs (opioids and local
anesthetics), and pregnancy or lactation.
2.2. Anesthetic Management
In the pre-anesthetic room, all enrolled patients were explained how to convey pain
intensity using a numerical rating scale (NRS; 0, no pain, and 10, worst pain possible), and
on how to use the PCEA device (PAINSTOP[PS-1000], Unimedics Co., Seoul, Korea) [16].
After transfer to the operating room, the blood pressure and pulse oximetry, and
electrocardiogram parameters were monitored in patients of both groups using a standard
monitor (Patient monitor M1205A, Philips, USA or Micro O2, Siemens, Germany). Insertion
of the epidural catheter was performed prior to the induction of general anesthesia. At
the T8/9 or T9/10 level, the catheter was advanced 5 cm cephalad through the epidural
space via a 17-gauge Touhy needle (Portex® Combined Spinal/Epidural Minipack with
Lock, pencil-point spinal needle, Smiths Med Int Ltd., Hythe, UK). After confirming that
blood or spinal fluid did not flow back through the epidural catheter, 3 mL of 1% lidocaine
(Daihan Lidocaine HCl 2% inj, Daihan, Seoul, Korea) was administered with the epidural
catheter, and sensory blockade was confirmed using a pinprick test.
Following intravenous administration of 0.2 mg of glycopyrrolate (Glycopyrrolate
injection, Reyon Pharm. Co. Ltd. Seoul, Korea), 1.5–2 mg/kg of propofol (Fresofol® MCT
1%, Fresenius Kabi Korea Ltd., Seoul, Korea), 0.5–1 µg/kg of remifentanil (Ultian injection,
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Hanlim Pharm. Co. Ltd., Seoul, Korea), and 0.6 mg/kg of rocuronium (Rocnium injection,
Hanlim Pharm. Co. Ltd., Seoul, Korea) were used to induce anesthesia.
Endotracheal intubation was performed when the patient’s reflex was absent. For
mechanical ventilation using a ventilator (Primus, Dräger Medical, Lübeck, Germany),
the following settings were used: tidal volume of 8 mL/kg, a positive end-expiratory
pressure of 5 cmH2O, and a respiratory rate to maintain the end-tidal carbon dioxide
level between 35 and 40 mmHg and oxygen saturation higher than 99% in 50% O2/air.
The maintenance of anesthesia was adjusted with 0.7–1.2 age-adjusted minimal alveo-
lar concentration of desflurane (Suprane®, Baxter Healthcare, Deerfield, IL, USA) and
remifentanil 0.05–0.1 µg/kg/min by targeting bispectral index (BIS) monitoring (Aspect
A-2000; Aspect Medical System Inc., Newton, MA, USA) scores at 40–60. The anesthetic
agents were titrated to maintain the mean blood pressure (MBP) and heart rate (HR) within
25% of baseline values and to provide an appropriate depth of anesthesia. Intraopera-
tive fluid was maintained using crystalloid fluid (Plasma solution A, CJ Pharmaceutical,
Seoul, Korea) at a constant rate of 5–10 mL/kg/h. Hypotension (MBP < 60 mm Hg) was
managed with intravenous ephedrine (Ephedrine HCl®, Daewon Pharmaceuticals, Seoul,
Korea) at 4 mg increments, and 0.25 mg intravenous atropine (Daehan Atropine, Daehan
Pharmaceutical, Seoul, Korea) was used to manage bradycardia (HR < 40 beats/min). At
the end of the surgery, 0.2 mg of glycopyrrolate and 1.0 mg of neostigmine (neostigmine
methylsulfate injection, Daihan Pharm. Co. Ltd. Seoul, Korea) were administered to
reverse neuromuscular blockade.
2.3. Randomization and Intervention
After enrollment, the patients were randomly assigned to two groups that used a
PAINSTOP device applying either the conventional fixed-rate basal infusion mode (CFIM
group, n = 38) or the variable-rate feedback infusion mode (VFIM group, n = 38) using a
computer-generated random table with no dividing blocks and stratification.
The PCEA regimen was a mixture of a total volume of 250 mL, comprising 0.15%
ropivacaine (Nacain Injection, Huons Co., Sungnam, Korea), 15 µg/kg of fentanyl (fentanyl
citrate injection, Hana Pharm Co. Ltd., Seoul, Korea), and normal saline in both groups. All
PCA devices were set to administer a bolus of 0.5 mL (fentanyl: 0.03 µg/kg) with a lockout
interval of 15 min and a basal infusion rate of 5 mL/h (fentanyl: 0.3 µg/kg/h). The basal
infusion rate in the VFIM group was set to increase automatically by 0.5 mL/h (fentanyl:
0.03 µg/kg/h) each time a bolus dose was administered by pushing the button and decrease
by 0.3 mL/h (fentanyl: 0.018 µg/kg/h) when a bolus dose was not administered for two
hours. The basal infusion rate was specified as a maximum flow rate of 7.5 mL/h (fentanyl:
0.45 µg/kg/h) and a minimum flow rate of 3 mL/h (fentanyl: 0.18 µg/kg/h). At the
initiation of peritoneal closure, the PCA device was commenced according to the group
assignment following the bolus injection of 5 mL of ropivacaine 0.15% via the epidural
catheter and 0.3 mg of intravenous ramosetron (Nasea injection, Astellas Pharma Korea
Inc., Seoul, Korea) for PONV.
Following the patients were arrived at the recovery room after surgery, instructions
on the use of the PCEA device were repeated. Patients were encouraged to press the bolus
button whenever the resting NRS score was 3 or higher. Recovery nurses who were not
part of the study assessed the resting NRS score, and additional rescue analgesics with
fentanyl at 0.5 µg/kg increments were administered to patients who experienced sustained
pain at a resining NRS score of >4 in the recovery room.
After discharge from the recovery room, postoperative pain, any adverse effects
related to PCEA, and the amounts of the consumed volume of PCEA were assessed at 1, 6,
24, 48 h after surgery. Similarly, for patients who experienced sustained pain at a resting
NRS score of >4 in the admission room, pethidine (Pethidine HCL, Jeil Pharm, Daegu,
Korea) was administered at increments of 12.5 mg.
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2.4. Data Collection
All data were collected prospectively. These included the registered demograph-
ics and intraoperative variables such as age, BMI, sex, ASA physical status, underlying
co-morbidities, type of gastrectomy, duration of anesthesia and operation, administered
amount of fluid intake, amount of blood loss, urine output, and dose of administered intra-
operative remifentanil and ephedrine. Intraoperative hemodynamic variables, including
MBP, HR, and BIS were also collected during the intraoperative period. The resting NRS
score; the amount of consumed volume of PCEA; the number of patients who received
additional rescue analgesics; and those who experienced any PCEA-related adverse effects
including nausea, vomiting, dizziness, hypotension, tachypnea, numbness, and pruritus
were assessed at 1, 6, 24, and 48 h after surgery. In addition, the duration of postoperative
hospital stays and the discontinuation rate of PCEA were evaluated.
2.5. Statistical Analysis
The primary endpoint of the current study was the resting pain intensity at six hours
after surgery. Based on a preliminary study, the resting NRS score at six hours after surgery
in the CFIM group was 4.05 ± 0.8 and 3.4 ± 0.5 in the VFIM group. Thirty-two patients in
each group were required in order to guarantee the power of 90% at a significance level of
5% for a difference of 0.65 in the resting NRS (standard deviation of 0.8). Considering a
15% dropout rate, 38 patients were recruited in each group.
For continuous variables, the Shapiro–Wilk test was used to test the normality of
data distribution. Statistical analysis was performed using Student’s t-test for normally
distributed continuous variables, including weight, BMI, and the duration of anesthesia
and surgery; these variables were presented as mean ± SD. For continuous variables that
were not normally distributed, including age; fluid intake; amount of blood loss; urine
output; intraoperative dose of remifentanil and ephedrine; intraoperative MBP, HR, and
BIS; postoperative NRS score; volume of PCEA consumed; and duration of postoperative
hospital stay, the Mann-Whitney U test was used to determine whether there was a sig-
nificant difference between the two groups, and data were presented as median [Q1, Q3].
For categorical variables, including sex, ASA physical status, underlying diseases such as
hypertension and diabetes, type of gastrectomy, number of patients who received addi-
tional rescue analgesics, number of patients who experienced any PCEA-related adverse
effects, and the discontinuation rate of PCEA, the data were presented as frequencies (%),
and significant relationships between groups and variables were determined using the
chi-square test. In the contingency table of groups and variables, if an expected frequency
of less than 5 occurred in more than 20% of the cells, Fisher’s exact test was used. Statistical
significance was set at p < 0.05. All statistical analyses were conducted by SAS (version
9.4; Cary, NC, USA) and R software (version 4.04; R Foundation for Statistical Computing,
Vienna, Austria).
3. Results
Among the 78 patients, two who did not meet the inclusion criteria were excluded.
Thus, 76 patients were finally enrolled, and these were randomly allocated to each of the
two groups. Following enrollment, discontinued intervention occurred for two patients
in each group: two in the CFIM group owing to a prolonged operation time and mas-
sive bleeding, and two in the VFIM group owing to a change in the operation plan and
massive bleeding. Thus, a total of 36 patients in each group were included for the final
analysis (Figure 1).
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Figure 1. Flow diagram depicting patient enrollment. CFIM, conventional fixed-rate infusion mode; VFIM, variable-rate
feedback infusion mode.
The demographic and intraoperative characteristics of the enrolled patients are pre-
sented in Table 1. There were no significant differences in demographic data, medical
history, duration, and doses of drugs used during anesthesia between the two groups. No
significant differences were observed in intraoperative MBP, HR, and BIS between the
two groups.
The NRS, total administered dose of PCEA, and the number of patients who received
rescue opioids at each time point are shown in Table 2. No differences were observed in the
total administered dose of PCEA and the number of patients who received the additional
opioids at each time point between the two groups.
At one to six hours after surgery, patients in the VFIM group had significantly less
pain than those in the CFIM group (4 [3, 6] vs. 3 [1, 5], respectively; p = 0.031) (Table 2 and
Figure 2A). However, there were no significant differences in the resting pain intensity
between the two groups at other time intervals. The number of patients who suffered from
postoperative nausea was significantly lower in the VFIM group than in the CFIM group
until six hours after surgery (Figure 2B and Table 3). However, at other time intervals, no
significant differences were observed between the two groups.
Int. J. Environ. Res. Public Health 2021, 18, 8777 6 of 11
Table 1. Demographic and intraoperative variables.
CFIM Group (n = 36) VFIM Group (n = 36) p Value
Age, years 57.5 [51, 60] 56.5 [49, 61] 0.969
Body mass index, kg/m2 22.5 ± 3.2 23.6 ± 2.8 0.114
Male sex 22 (61%) 27 (75%) 0.206
ASA physical status, I/II/III 21/14/1 18/18/0 0.343
Comorbidities
Hypertension 5 (14%) 8 (22%) 0.358
Diabetes mellitus 6 (17%) 4 (11%) 0.496
Subtotal/Total 25/11 26/10 0.795
Anesthesia time, min 182.7 ± 32.8 174.4 ± 31.6 0.278
Operation time, min 145.7 ± 32.8 138.2 ± 32.6 0.403
Fluid intake, mL 1200 [1050, 1400] 1200 [1000, 1500] 0.796
Blood loss, mL 135 [70, 235] 100 [77.5, 200] 0.578
Urine output, mL 157.5 [110, 280] 142.5 [97.5, 250] 0.325
Administered amounts of
remifentanil, µg 524 [432, 681] 513 [433, 576] 0.450
Administered amounts of
ephedrine, mg 6 [0, 8] 4 [0, 12] 0.862
Mean blood pressure, mmHg
0 min 89.1 ± 15.5 85.8 ± 13.7 0.346
30 min 87.3 ± 12.7 86.2 ± 11.8 0.707
60 min 92.1 ± 11.6 87.3 ± 9.9 0.060
90 min 88.3 ± 12.4 85.2 ± 9.0 0.253
Heart rate, bpm
0 min 72 [63, 79] 66 [63, 74] 0.245
30 min 80 [70, 89] 79 [66, 86] 0.456
60 min 75 [67, 82] 71 [65, 78] 0.195
90 min 73 [67, 77] 68 [63, 74] 0.056
Bispectral index
0 min 43 [36, 56] 40 [35, 46] 0.247
30 min 40 [33, 46] 38 [35, 42] 0.298
60 min 38 [30, 46] 35 [30, 40] 0.111
90 min 35 [28, 43] 32 [29, 36] 0.272
Data are presented as mean ± standard deviation, median [Interquartile range], or number of patients (proportion).
ASA, American Society of Anesthesiologists; Subtotal, subtotal gastrectomy; Total, total gastrectomy; CFIM,
conventional fixed-rate infusion mode; VFIM, variable-rate feedback infusion mode.
Table 2. Postoperative pain-related profile up to 48 h after surgery.
CFIM Group (n = 36) VFIM Group (n = 36) p Value
NRS
0–1 h 7 [5.5, 8] 7 [5.5, 8] 0.613
1–6 h 4 [3, 6] 3 [1, 5] 0.031 *
6–24 h 4 [3, 5] 3 [2, 5] 0.137
24–48 h 4 [3, 5] 3 [2, 5] 0.538
Administered dose of PCEA
0–1 h 6.08 [5.37, 7.69] 6.24 [5.49, 7.35] 0.503
1–6 h 27.4 [19.31, 32.54] 28.32 [17.19, 36] 0.305
6–24 h 97.74 [86.4, 108.29] 99.16 [84.04, 122.06] 0.540
24–48 h 215.92 [204.47, 227.84] 207.15 [166.73, 250] 0.953
Number of patients who received rescue opioids
0–1 h 28 (78%) 22 (61%) 0.125
1–6 h 22 (61%) 19 (53%) 0.475
6–24 h 20 (56%) 17 (47%) 0.479
24–48 h 14 (39%) 17 (47%) 0.475
Data are presented as median [Interquartile range] or number of patients (proportion). * p < 0.05. NRS, numeric
rating score; PCEA, patient controlled epidural analgesia; CFIM, conventional fixed-rate infusion mode; VFIM,
variable-rate feedback infusion mode.
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Figure 2. Resting numeric rating score of pain intensity (A) and the number of patients who experienced postoperative
nausea (B). Box plot with median (solid line), interquartile range (box), and values within 1.5 times the interquartile
range (whiskers) are shown. * p < 0.05. NRS, numeric rating score; CFIM, conventional fixed-rate infusion mode; VFIM,
variable-rate feedback infusion mode.
Table 3. Postoperative adverse effects up to 48 h after surgery.
CFIM Group (n = 36) VFIM Group (n = 36) p Value
Postoperative hospital stays, days 7 [6, 7.5] 7 [6, 8] 0.394
Nausea
0–1 h 10 (28%) 1 (3%) 0.003 *
1–6 h 9 (25%) 2 (6%) 0.022 *
6–24 h 9 (25%) 6 (17%) 0.384
24–48 h 7 (19%) 5 (14%) 0.527
Vomiting
0–1 h 1 (3%) 0 (0%) >0.999
1–6 h 0 (0%) 0 (0%) -
6–24 h 0 (0%) 1 (3%) >0.999
24–48 h 0 (0%) 0 (0%) -
Dizziness
0–1 h 2 (6%) 1 (3%) >0.999
1–6 h 2 (6%) 1 (3%) >0.999
6–24 h 2 (6%) 5 (14%) 0.429
24–48 h 4 (11%) 4 (11%) >0.999
Hypotension
0–1 h 2 (6%) 0 (0%) 0.493
1–6 h 1 (3%) 1 (3%) >0.999
6–24 h 2 (6%) 7 (19%) 0.151
24–48 h 1 (3%) 3 (8%) 0.614
Tachypnea
0–1 h 0 (0%) 2 (6%) 0.493
1–6 h 0 (0%) 1 (3%) >0.999
6–24 h 0 (0%) 0 (0%) -
24–48 h 0 (0%) 0 (0%) -
Numbness
0–1 h 0 (0%) 0 (0%) -
1–6 h 1 (3%) 0 (0%) >0.999
6–24 h 1 (3%) 0 (0%) >0.999
24–48 h 0 (0%) 0 (0%) -
Pruritus
0–1 h 0 (0%) 0 (0%) -
1–6 h 0 (0%) 0 (0%) -
6–24 h 0 (0%) 0 (0%) -
24–48 h 1 (3%) 1 (3%) >0.999
Discontinuation of PCEA 2 (6%) 3 (8%) >0.999
Data are presented as median [Interquartile range] or number of patients (proportion). * p < 0.05. CFIM,
conventional fixed-rate infusion mode; VFIM, variable-rate feedback infusion mode.
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The data on the duration of postoperative hospital stays and PCEA-related adverse
effects following surgery are summarized in Table 3.
As seen from the table, the postoperative hospital stay was not significantly different
between the groups. Other PCEA-related adverse effects such as vomiting, dizziness,
hypotension, tachypnea, numbness, and pruritus were also not significantly different
between the two groups. In addition, with respect to the rate of discontinuation of PCEA, no
difference was observed between the groups (one each with hypotension and uncontrolled
nausea in the CFIM group vs. two with hypotension and one with uncontrolled fever in
the VFIM group; p > 0.999).
4. Discussion
This prospective randomized controlled trial demonstrated that a VFIM of PCEA may
provide better analgesia that is accompanied by significantly less nausea in six hours after
surgery than CFIM in patients after open gastrectomy.
Determining an appropriate infusion rate requires consideration of several factors
including BMI, sex, and age, which can influence the efficacy of PCEA [11,13,17,18]. In
addition, the degree of pain and demand for analgesics may change over time after surgery.
Generally, postoperative pain intensity is more severe on the day of surgery; the degree and
frequency decrease over time [19,20]. Therefore, background infusion of a constant fixed-
rate dose may not effectively meet these needs. However, a variable-rate feedback infusion
dose change mode may compensate for these disadvantages by reflecting patient demand.
In the present study, the patients in the VFIM group reported significantly less resting
pain intensity at one to six hours after surgery, which was the primary endpoint of the
study. However, there was no significant difference in the resting NRS score between
the two groups immediately after arriving at the recovery room. The dose infused in the
recovery room may not have had enough time to make a difference in the analgesic effect
depending on the PCEA background dose change modality. The bolus injection of a local
anesthetic at the end of the surgery would have provided similar analgesic effects in both
groups, and residual anesthesia may have been affected. It is likely that the significant
difference in the resting pain intensity at one to six hours after surgery was affected by the
difference in the background infusion dose change modality.
There are few reports that have documented the usefulness of variable-rate feedback
infusion control of the basal infusion rate in epidural analgesia. Generally, it is considered
that higher analgesic doses of PCEA may provide better analgesia; however, previous
studies have reported that higher analgesic doses of PCEA are not always associated
with better pain control [21]. Pain is defined as “an unpleasant sensory and emotional
experience associated with or resembling that associated with actual or potential tissue
damage” [22]. Such pain has many subjective elements, and these subjective emotions
may respond sensitively to changes in the intensity of stimuli [23]. Therefore, appropriate
analgesic dose changes in response to changing pain stimuli may lead to better pain control.
In the present study, the dose of analgesic increased more steeply in the early postoperative
period and then gradually decreased in the VFIM group. It is possible that patients in this
group would have responded more effectively to the stimulation of postoperative pain,
which is generally more severe in the early postoperative period.
Pain threshold can be affected by several factors, such as age, sex, and psychological
factors [17,24,25]. It is very difficult to determine the most effective basal infusion dose by
considering only these factors. In contrast, adjusting the dose by reflecting the patient’s
requirements can lead to a reduced probability of using the inadequate analgesic dose,
which has been demonstrated in the present study as a better early postoperative analgesia.
PCEA is associated with the development of several adverse effects [1,11]. Among
these, nausea is one of the most common complications [1]. The chemoreceptor-triggering
zone, which is located within the area postrema, is known to induce nausea and vomiting
reactions by detecting substances potentially harmful to the body [26]. Administration of
opioids or local anesthetics into the epidural space can often cause nausea by stimulating
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this mechanism. Many risk factors for PONV have been identified [26,27]. As mentioned
above, it might be difficult to determine the appropriate basal infusion dose by considering
all these factors. However, adjustment of the infusion rate according to the pain intensity of
the patient may have contributed to the amount of titration of the infusion after reflecting
the different characteristics of each patient. Although further research is required, a possible
explanation for the significantly lower incidence of nausea in the VFIM group in the present
study may be attributed to the reduction in the number of patients receiving excessive
chemical stimuli.
It has been documented that the intensity of postoperative pain also affects the in-
cidence of nausea [28,29]. It has been shown that pain is a major risk factor for nausea
than the administration of analgesics [29]. Pain itself induces general arousal of the central
nervous system, which can lead to vomiting by other stimuli. In addition, activation of
nociceptors owing to pain can cause changes in the central nervous system, the vomiting
threshold, and the chemoreceptor trigger zone [29]. In the present study, compared with
the CFIM group, the VFIM group had significantly less nausea in accordance with the
significantly lower resting NRS during the early postoperative period (one to six hours).
This may be another explanation for this mechanism.
The study has some limitations. First, only Korean patients with gastric cancer who
underwent open gastrectomy were enrolled. Consequently, the study was conducted on
a sample with an unintentionally narrow age and gender distribution. Therefore, the
results of this study are difficult to be applied to patients with different characteristics or
undergoing different surgeries. In addition, the small sample size might not have been
sufficient to discriminate the difference in pain intensity or adverse effects at other time
intervals. With a larger sample size, perhaps, it might have been possible to compare
more accurately as to whether there were any differences in other adverse effects or in
other time intervals. Nevertheless, this study is meaningful in showing the possibility that
basal infusion control according to the patient’s needs with the epidural route can be an
effective approach.
5. Conclusions
Our study shows that VFIM, in which the basal rate was adjusted according to
the administration of a bolus dose, provided better analgesia with less nausea in the
early postoperative period than the CFIM of fentanyl/ropivacaine-based PCEA after
open gastrectomy.
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